peptideNot FDA-approvedResearch chemicalTabimorelin was developed by Novo Nordisk as an investigational oral growth hormone secretagogue but was never approved or marketed as a drugIt has no legal supplement or prescription status in the US; the cited literature covers only early-phase clinical pharmacology trials
TabimorelinBenefits, Dosage & Interactions
Tabimorelin is a synthetic peptide that functions as a growth hormone secretagogue, meaning it stimulates the body to release its own growth hormone (GH). Research on Tabimorelin focuses on muscle and strength. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials published.
Plasma half-life
Characterized in the cited single- and multiple-dose pharmacokinetic studies in healthy male volunteers
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Healthy-volunteer studies used single and repeated oral doses in the milligram-per-kilogram range escalated across dose cohorts[1][2]
- Route studied
- Oral (tabimorelin, unlike peptide GH secretagogues, was developed specifically as an orally active compound)[1][2]
Reported for Tabimorelin in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Tabimorelin entry is written from. Each number matches an inline marker above.
- [1]The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteersZdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, Falch JE, Ilondo MM · Growth Hormone & IGF Research · 2000 · Peer-reviewed · PMID 11032702
- [2]The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjectsZdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, Søgaard B, Ynddal L, Ilondo MM · Growth Hormone & IGF Research · 2001 · Peer-reviewed · PMID 11437473
- [3]A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrateZdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM · European Journal of Clinical Pharmacology · 2003 · Peer-reviewed · PMID 12610745
How to track Tabimorelin doses
Tabimorelin is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Tabimorelin is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Tabimorelin comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review Tabimorelin alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Tabimorelin dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Tabimorelin studied for?
What is Tabimorelin?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Tabimorelin is a synthetic peptide that functions as a growth hormone secretagogue, meaning it stimulates the body to release its own growth hormone (GH). It was developed and investigated for its potential therapeutic applications, particularly in conditions characterized by GH deficiency or where increased GH levels could be beneficial. Unlike exogenous growth hormone administration, tabimorelin aims to enhance physiological GH secretion by acting on the pituitary gland.
The peptide interacts with ghrelin receptors, also known as growth hormone secretagogue receptors (GHSRs). These receptors are found in various tissues, including the hypothalamus and pituitary, where they play a crucial role in regulating appetite, energy balance, and growth hormone release. By activating these receptors, tabimorelin mimics the action of ghrelin, a naturally occurring hormone. Early research on tabimorelin focused on its ability to increase GH and insulin-like growth factor 1 (IGF-1) levels, which are important for tissue growth, metabolism, and overall cellular function. Its development was part of a broader effort to find orally active compounds that could modulate the growth hormone axis. (Source: PubChem, DrugBank)
What does the research say about Tabimorelin?
Tap a section to expand.
Tabimorelin exerts its effects by selectively binding to and activating the growth hormone secretagogue receptor 1a (GHSR-1a), which is located predominantly in the anterior pituitary gland and the hypothalamus. This receptor is the primary target for ghrelin, an endogenous peptide hormone. When tabimorelin binds to GHSR-1a, it triggers a signaling cascade within the pituitary somatotrophs, leading to the increased synthesis and release of growth hormone (GH) into the bloodstream.
This activation bypasses the negative feedback loop of GH, meaning it can stimulate GH release even when endogenous GH levels are already regulated. The pulsatile release of GH induced by tabimorelin is thought to be more physiological compared to the constant levels achieved with exogenous GH administration. The elevated GH levels, in turn, stimulate the liver and other tissues to produce insulin-like growth factor 1 (IGF-1). IGF-1 is a key mediator of many of the growth-promoting and metabolic effects associated with growth hormone, including protein synthesis, cell proliferation, and glucose metabolism. The specific interaction with GHSR-1a distinguishes tabimorelin from other GH-releasing agents that might act via different mechanisms. (Source: DrugBank, NIH PubMed research literature)
Source for this section: Sources for How does Tabimorelin work?: Jumps to this entry in the sources and references list at the end of the page.
Research into tabimorelin has largely focused on its ability to increase growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, which are critical for various physiological processes. The primary potential benefits investigated include:
* **Muscle Mass and Strength:** Due to its GH-releasing properties, tabimorelin has been explored for its potential to promote protein synthesis and enhance muscle anabolism. Elevated GH and IGF-1 levels are generally associated with improvements in lean body mass and skeletal muscle function, an area of interest for individuals looking to support muscle development. (Source: NIH PubMed research literature)
* **Bone Mineral Density:** Growth hormone and IGF-1 play a significant role in bone metabolism. Studies have indicated that secretagogues, by increasing these hormones, could potentially contribute to maintaining or improving bone mineral density, which is relevant for bone health. (Source: Academic research databases)
* **Metabolic Effects:** GH influences carbohydrate and lipid metabolism. By modulating GH levels, tabimorelin might have implications for body composition, potentially affecting fat distribution and glucose utilization. (Source: Published scientific studies)
* **General Well-being and Recovery:** While not a direct effect, optimal growth hormone levels are often linked to improved recovery from physical stress and a sense of general vitality. The increase in GH and IGF-1 induced by tabimorelin could indirectly support these aspects. (Source: Review articles on growth hormone secretagogues)
Clinical evidence for tabimorelin primarily stems from early-phase human trials and preclinical studies. These investigations aimed to characterize its pharmacological profile and evaluate its efficacy in stimulating growth hormone (GH) release. Studies have consistently demonstrated that tabimorelin effectively increases pulsatile GH secretion in healthy adults and in individuals with specific medical conditions. For instance, research published in peer-reviewed journals has shown that oral administration of tabimorelin leads to a dose-dependent increase in both GH and insulin-like growth factor 1 (IGF-1) levels, crucial markers for growth hormone activity.
In the context of muscle growth and athletic performance, the evidence is largely indirect, based on the known anabolic effects of GH and IGF-1. While tabimorelin has been shown to elevate these hormones, direct evidence linking tabimorelin specifically to significant long-term improvements in muscle mass or strength in healthy, exercising individuals is less established from published clinical trials. The focus of most research was on its therapeutic potential for growth hormone deficiency or catabolic conditions rather than as a general performance enhancer. Further large-scale, long-term studies would be needed to definitively establish these benefits in various populations. (Source: Research articles cited in PubMed, scientific reviews on GH secretagogues)
As with any compound affecting hormonal systems, tabimorelin may be associated with various side effects. Common side effects observed in clinical studies and reported in literature for growth hormone secretagogues generally include:
* **Headache:** Some individuals may experience mild to moderate headaches.
* **Nausea:** Gastrointestinal discomfort, including nausea, has been reported.
* **Dizziness:** Feelings of lightheadedness or dizziness may occur.
* **Increased Appetite:** Due to its action on ghrelin receptors, an increase in appetite is a possible side effect.
* **Fluid Retention:** Mild edema or fluid retention can sometimes be observed, similar to other growth hormone-stimulating agents.
* **Hypoglycemia (low blood sugar):** While growth hormone itself can sometimes elevate blood sugar, the initial release can occasionally lead to transient drops.
* **Injection site reactions (if administered subcutaneously):** Although oral forms were developed, if an injectable form is used, pain, redness, or swelling at the injection site are possible.
More significant side effects are less common but could potentially include alterations in glucose metabolism or impacts on the cardiovascular system, especially with prolonged use or in susceptible individuals. Individuals should monitor for any unusual or concerning symptoms and discuss them with a healthcare professional.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals considering tabimorelin should be aware of several warnings. Because tabimorelin stimulates the release of growth hormone (GH), it can have systemic effects that may be undesirable or dangerous in certain circumstances. Increased GH and IGF-1 levels can potentially impact glucose metabolism, leading to changes in blood sugar levels. Individuals with diabetes or those at risk of developing diabetes should exercise particular caution and have their glucose levels monitored regularly. There is also a theoretical concern that elevated GH and IGF-1 levels, if maintained over long periods, could stimulate the growth of certain tissues, including potentially existing neoplastic cells, although this concern is largely extrapolated from observations with exogenous GH.
Furthermore, the long-term effects of chronic GH secretagogue use are not fully established, particularly in healthy individuals. The compound's interaction with the ghrelin receptor may also influence appetite and energy balance, which could have implications for body weight. Pregnant or breastfeeding individuals should avoid tabimorelin due to insufficient safety data for these populations. Always disclose all health conditions and medications to a healthcare provider before initiating tabimorelin to ensure safety and appropriateness.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Tabimorelin is contraindicated in several situations where its use could pose significant risks. These contraindications are primarily based on the known physiological effects of increased growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels induced by secretagogues. Absolute contraindications typically include:
* **Active Malignancy (Cancer):** Because GH and IGF-1 can promote cell growth, tabimorelin is generally contraindicated in individuals with active cancer or a history of certain types of cancer, due to the theoretical risk of stimulating tumor progression. This is a critical consideration.
* **Diabetic Retinopathy:** Individuals with diabetic retinopathy may be at increased risk of exacerbation with elevated GH/IGF-1 levels.
* **Known Hypersensitivity:** A history of allergic reaction or hypersensitivity to tabimorelin or any of its excipients would contraindicate its use.
* **Pregnancy and Breastfeeding:** There is insufficient data to establish safety during pregnancy or lactation, and thus, its use is contraindicated in these populations to avoid potential harm to the fetus or infant.
* **Untreated Pustular Acne:** While less common, in some cases, GH stimulation can worsen acne.
Other conditions might warrant extreme caution or make the compound unsuitable on a case-by-case basis, such as kidney or liver impairment, severe cardiovascular disease, or active acute critical illness. A thorough medical evaluation is necessary to determine appropriateness.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
When considering tabimorelin, it is important to be aware of potential interactions with other substances that could alter its effects or increase the risk of adverse reactions. As tabimorelin influences the growth hormone axis, compounds that also affect this system or related endocrine pathways may interact. Specific substances to consider include:
* **Glucocorticoids (e.g., Prednisone, Dexamethasone):** These medications can suppress growth hormone release and may blunt the effectiveness of tabimorelin.
* **Somatostatin and its Analogs (e.g., Octreotide):** Somatostatin is a natural inhibitor of GH release. Co-administration would likely counteract the GH-stimulating effects of tabimorelin.
* **Insulin and Oral Antidiabetic Agents:** Since tabimorelin can affect glucose metabolism, concomitant use with antidiabetic medications requires careful monitoring to prevent hypoglycemia or hyperglycemia. Adjustments to antidiabetic medication dosages may be necessary.
* **Other Growth Hormone-Releasing Peptides or Medications:** Combining tabimorelin with other growth hormone secretagogues could potentially lead to excessive GH elevation, increasing the risk of side effects.
* **Estrogens:** High doses of estrogens can sometimes increase GH levels, which might interact with tabimorelin's effects.
Always provide a complete list of all prescription medications, over-the-counter drugs, herbal supplements, and other compounds being used to a healthcare professional to identify potential interactions and ensure safe use.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for tabimorelin administration, when studied, has often involved once or twice daily dosing, reflecting the pulsatile nature of natural growth hormone release. While its half-life is relatively short, approximately 2 hours, its effects on stimulating growth hormone (GH) secretion can persist for several hours. As a growth hormone secretagogue, tabimorelin aims to enhance physiological GH pulses rather than provide a constant elevation. The decision on the exact timing, whether it's in the morning, before sleep, or at other specific times, has varied across research protocols and depends heavily on the specific therapeutic goals and individual response.
Some research protocols have explored evening administration to mimic the natural nocturnal surge of growth hormone. However, without specific directions from a licensed clinician, it's not possible to provide definitive guidance. The compound can generally be taken with or without food, as indicated by its "either" food rule, suggesting that food intake does not critically impair its absorption or efficacy. Individual needs vary significantly when it comes to any compound affecting the endocrine system. Therefore, consultation with a licensed clinician is necessary to determine the most appropriate timing for administration, should the compound be used under medical supervision. (Source: Research literature, DrugBank)
Source for this section: Sources for When should you take Tabimorelin?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Tabimorelin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Tabimorelin
Tabimorelin is a research peptide. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Tabimorelin is commonly discussed in the context of supporting muscle. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Tabimorelin, it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
Tabimorelin carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a peptide, Tabimorelin can overlap with other supplements, prescription medicines, hormones and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Tabimorelin with no sign-up.
Whether Tabimorelin fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Tabimorelin. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Tabimorelin varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Tabimorelin depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Tabimorelin the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Tabimorelin?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate(opens PubMed in a new tab)Eur J Clin Pharmacol · 2003 · PMID 12610745 · https://pubmed.ncbi.nlm.nih.gov/12610745/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 9810101(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/9810101
Verify at
Publisher search links for Tabimorelin. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Tabimorelin?
Plain-text summary, safe to quote verbatim:
Tabimorelin is a synthetic peptide that functions as a growth hormone secretagogue, meaning it stimulates the body to release its own growth hormone (GH). Research on Tabimorelin focuses on muscle and strength. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
Source: DoseRoutine — https://doseroutine.com/library/tabimorelin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Tabimorelin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/tabimorelin
What compounds are similar to Tabimorelin?
Others in the peptide category or studied for the same goals.
Which goals is Tabimorelin used for?
Other compounds studied for the same benefits as Tabimorelin.
Continue exploring
See every compound DoseRoutine catalogs for these goals.